Company MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
40.85 ^USD	+2.23%		+2.77%	-32.36%

May. 07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
May. 07	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Number of employees: 50

Managers	Title	Age	Since
Jorge da Silva FOU	Founder	47	22-04-04
Kristian Reich FOU	Founder	58	22-04-04
Matthias Bodenstedt DFI	Director of Finance/CFO	36	22-04-04
Dragos Budinschi CTO	Chief Tech/Sci/R&D Officer	-	-
Joao Neves CTO	Chief Tech/Sci/R&D Officer	-	-
Oliver Daltrop CTO	Chief Tech/Sci/R&D Officer	47	21-08-31
Nuala Brennan CTO	Chief Tech/Sci/R&D Officer	55	21-08-31
Nicolas Mosimann LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Simon Sturge CHM	Chairman	65	22-04-04
Catherine Moukheibir BRD	Director/Board Member	64	22-04-04
Spike N. Loy BRD	Director/Board Member	43	22-04-04
Andrew Phillips BRD	Director/Board Member	53	22-04-04
Ramnik Xavier BRD	Director/Board Member	62	22-04-04
Jorge da Silva FOU	Founder	47	22-04-04
Kara Lassen BRD	Director/Board Member	45	22-04-04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	995,267	0	0	84.73 %
Stock B	1	62,874,637	53,272,877 ( 84.73 %)	0

Name	Equities	%	Valuation
BVF, Inc. 36.29 %	21,751,284	36.29 %	919 M $
Cormorant Asset Management LP 14.17 %	8,494,151	14.17 %	359 M $
Fidelity Management & Research Co. LLC 7.292 %	4,370,652	7.292 %	185 M $
Jorge da Silva 4.976 %	2,982,814	4.976 %	126 M $
Kristian Reich 4.951 %	2,967,554	4.951 %	125 M $
MERCK KGAA 4.650 %	2,787,509	4.650 %	118 M $
Avoro Capital Advisor LLC 4.304 %	2,580,000	4.304 %	109 M $
Citadel Securities GP LLC 3.853 %	2,309,433	3.853 %	98 M $
Adage Capital Partners GP LLC 3.812 %	2,284,913	3.812 %	97 M $
T Rowe Price Associates, Inc. (13F Subfiler) 3.563 %	2,135,883	3.563 %	90 M $

Name	Equities	%	Valuation
Matthias Bodenstedt 3.287 %	294,473	3.287 %	12 M $
Jorge da Silva 2.191 %	196,316	2.191 %	8 M $
Kristian Reich 2.191 %	196,316	2.191 %	8 M $

MoonLake Immunotherapeutics

Dorfstrasse 29

6300, Zug

http://www.moonlaketx.com

address MoonLake Immunotherapeutics(MLTX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.85 USD

Average target price

73.31 USD

Spread / Average Target

+79.46%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MOONLAKE IMMUNOTHERAPEUTICS	-32.36%	2.57B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.22%	21.78B
GENMAB A/S	-9.10%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs